Information on the Total Number of Voting Rights (Denominator) following
Conversion Notices from Atlas
Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion
resulting in a EUR 150,000 capital increase. This is part of Atlas Special
Opportunities, LLC's EUR 20 million Capital Commitment(1) that will allow
Oxurion to focus on developing innovative therapeutics to preserve the vision of
elderly people, targeting potential market opportunities of USD 3-6 billion.
Leuven, BELGIUM - 04 March, 2024 - 07.00 PM CET - In accordance with article 15
of the Belgian Act of May 2, 2007 on the disclosure of major participations in
issuers of which shares are admitted to trading on a regulated market and
regarding miscellaneous provisions, Oxurion NV (https://www.oxurion.com/)
(Euronext Brussels: OXUR) (the "Company" or "Oxurion"), announces the below
information, following the issuance of 815,217,391 new ordinary shares on
February 29, 2024, for a total amount of EUR 150,000 pursuant to the Capital
Commitment entered into with Atlas Special Opportunities, LLC.
Following completion of capital increase through the conversion of the
convertible bonds, the total number of shares issued by Oxurion amounts to
5,753,951,723 outstanding ordinary shares carrying voting rights (compared to
4,938,734,332 outstanding ordinary shares previously). This number will be used
as the denominator for the calculation of the percentages of shareholdings.
Therefore, Oxurion publishes the following updated information:
* Share capital (EUR) 84,056,161.32
* Total number of securities with
voting rights (all ordinary shares) 5,753,951,723
* Total number of ordinary shares (=
denominator) 5,753,951,723
* Number of outstanding, granted rights
to subscribe to securities carrying
voting rights not yet issued
(excluding any shares resulting (a)
from the potential conversion of any
convertibles bonds issued on December
20, 2021 to the benefit of Kreos
Capital VI (UK) Limited, Pontifax
Medison Finance (Israel) L.P. and
Pontifax Medison Finance (Cayman)
L.P. or (b) from the exercise of any
subscription rights issued by the
Company to the benefits of employees,
consultants or directors of the
Company (as they are both currently
significantly out-of-the-money):
* 304 convertible bonds issued on March 14, 2023, April 20, 2023, May
22, 2023, June 15, 2023, August 10, 2023, September 15, 2023, October
20, 2023, October 24, 2023, November 15, 2023 and November 15, 2023,
January 9, 2024 and February 2, 2024, entitling its holder, Atlas Special
Opportunities, LLC, to subscribe to a total number of securities carrying
voting rights (all ordinary shares) in accordance with the terms and
conditions of these convertible bonds pursuant to the Subscription
Agreement entered into between the Company and Atlas Special
Opportunities, LLC on March 1, 2023, as amended on September 10, 2023 and
December 22, 2023.
END
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation
standard of care ophthalmic therapies for the treatment of retinal disease.
Oxurion is based in Leuven, Belgium. More information is available at
www.oxurion.com (http://www.oxurion.com).
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume any obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events, or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained in
the Company's Annual Report. This press release does not constitute an offer or
invitation for the sale or purchase of securities or assets of Oxurion in any
jurisdiction. No securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933, as amended,
or in compliance with an exemption therefrom, and in accordance with any
applicable U.S. state securities laws.
Please contact for additional information:
+-------------------------------------+----------------------------------------+
|Oxurion NV |Backstage Communication |
|Pascal Ghoson |Jurgen Vluijmans |
|Chief Executive Officer |Partner |
|pascal.ghoson@oxurion.com |jurgen@backstagecom.be |
|(mailto:pascal.ghoson@oxurion.com) |(mailto:jurgen@backstagecom.be) |
| | |
+-------------------------------------+----------------------------------------+
--------------------------------------------------------------------------------
1 Press release Oxurion, 02/03/2023 (https://ir.oxurion.com/news-releases/news-
release-details/oxurion-announces-subscription-agreement-atlas-providing-
company)
Â